AMNEAL PHARMACEUTICALS, INC. Litigation Settlement Interest
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Litigation Settlement Interest of $700.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-08.
Discontinued › Notes › Commitment and Contingencies › Loss Contingency › Litigation Settlement
us-gaap:LitigationSettlementInterest · last filed 2023-08-08
- AMNEAL PHARMACEUTICALS, INC. litigation settlement interest for the quarter ending 2023-06-30 was -$400.00K.
- AMNEAL PHARMACEUTICALS, INC. litigation settlement interest for the quarter ending 2023-03-31 was $1.10M.
- AMNEAL PHARMACEUTICALS, INC. litigation settlement interest for the quarter ending 2022-12-31 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. litigation settlement interest for the quarter ending 2022-09-30 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. litigation settlement interest for fiscal 2022 was $2.20M.
| Period end | Litigation Settlement Interest 3 month | Litigation Settlement Interest 6 month | Litigation Settlement Interest 9 month | Litigation Settlement Interest 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $700.00K 10-Q · filed 2023-08-08 | $700.00K derived: sum of 3 quarters · filed 2023-08-08 | $700.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | $1.10M 10-Q · filed 2023-05-09 | $1.10M derived: sum of 2 quarters · filed 2023-05-09 | $1.10M derived: sum of 3 quarters · filed 2023-05-09 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $0.00 derived: sum of 2 quarters · filed 2023-03-03 | $2.20M 10-K · filed 2023-03-03 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $2.20M 10-Q · filed 2022-11-07 | ||
| 2022-06-30 | $2.20M 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |